Ultragenyx, Mereo miss second interim analysis of closely-watched trial Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T W Thu F 10 July, 2025

The biotech companies everyone will be talking about in 2025 get revealed live in Boston this September. Endpoints 11 isn’t just any list — it’s where industry insiders gather to see which bold bets might pay off. Find out who wins in real time at the State Room — reserve your spot now and save with the Early Bird rate.

presented by Un­cov­er­ing the Po­ten­tial of Tar­get­ing the CD38 Path­way for Im­mune-Me­di­at­ed Dis­eases

spotlight Post-Hoc Live: Is China a threat or investment opportunity for the US? Live with Curie.Bio CEO Zach Weinberg

news Biotech’s Q2 numbers paint a picture of the good, the bad and the ugly Who pays the most in biopharma? We analyzed median pay at 177 companies Ultragenyx, Mereo’s bone disease drug fails second interim analysis, stocks plummet Swiss and German radiopharma biotech Nuclidium collects $99M Series B Kidney health biotech emerges with $54M to follow in Vertex’s footsteps Aqtual raises $31M to guide rheumatoid arthritis treatments

Jul 10 11:00am ET Beyond the data deluge: Immune profiling in early immuno-oncology trials sponsored by Precision for Medicine Jul 22 2:00pm ET New data from ASCO 2025 & clinical performance of Natera’s ultra-sensitive MRD platform sponsored by Natera Jul 24 12:00pm ET Predict tumor response and identify more patients for therapy with epigenomic biomarkers sponsored by Guardant

Post-Hoc Live is now available to stream. Catch full episodes on YouTube or listen on Spotify and Apple Podcasts. Be sure to subscribe so you don’t miss what’s next.

endpoints pharma Q&A: Retiring Arvinas CEO John Houston talks PROTACs, investor confidence and what’s next with Pfizer Federal judge sides with FDA on its mifepristone safety program CoRegen closes $93M financing round to enter the clinic and expand its leadership team FDA’s pediatric adcomm votes to continue surveillance of 21 drugs, three vaccines

in case you missed it 1. Updated: Merck drops $10B for respiratory drugmaker Verona Pharma in its first acquisition of 2025 2. Nimble radiopharma biotech Actithera gets $75M to enter the clinic 3. Trump’s CDC nominee Monarez advances to full Senate 4. AstraZeneca’s Alexion inks AAV capsid deal with JCR Pharma 5. Rhythm says o